Cuba vs Netherlands: Statin use vs. average non-HDL cholesterol levels
Cuba
3.3
in 2018
Netherlands
3.3
in 2018
Cuba rank
95th
Netherlands rank
95th
Statin use vs. average non-HDL cholesterol levels over time
- Cuba
- Netherlands
How they compare
Cuba currently reports 3.3 against 3.3 in Netherlands, a difference of 0.
Across all 39 years both countries report, Netherlands has been ahead every year.
Cuba ranks 95th and Netherlands ranks 95th of 191 countries.
Netherlands has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Cuba | Netherlands | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 3.6 | 4.43 | 0.83 | Netherlands |
| 1990s | 3.51 | 4.17 | 0.66 | Netherlands |
| 2000s | 3.4 | 3.73 | 0.33 | Netherlands |
| 2010s | 3.33 | 3.4 | 0.0667 | Netherlands |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, Cuba or Netherlands?
- Cuba, at 3.3 against 3.3 in Netherlands as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between Cuba and Netherlands?
- 0, with Cuba ahead.
- How many years of comparable data are there for Cuba and Netherlands?
- 39 years are reported by both, from 1980 to 2018.
- How do Cuba and Netherlands rank globally for statin use vs. average non-hdl cholesterol levels?
- Cuba ranks 95th and Netherlands ranks 95th of 191 countries.
- Where does this data come from?
- World Health Organization – Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.